PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
10.71%
Some net income increase while AXSM is negative at -488.37%. John Neff would see a short-term edge over the struggling competitor.
-1.40%
Negative yoy D&A while AXSM is 0.00%. Joel Greenblatt would note a short-term EPS advantage unless competitor invests for future advantage.
No Data
No Data available this quarter, please select a different quarter.
-49.10%
Negative yoy SBC while AXSM is 1545.18%. Joel Greenblatt would see less immediate dilution advantage if talent levels remain strong.
5.95%
Slight usage while AXSM is negative at -124.91%. John Neff would note competitor possibly capturing more free cash unless expansions are needed here.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-23.80%
Both negative yoy AP, with AXSM at -84.11%. Martin Whitman would find an overall trend toward paying down supplier credit in the niche.
823.30%
Some yoy usage while AXSM is negative at -680.00%. John Neff would see competitor possibly generating more free cash from minor accounts than we do.
59.87%
Well above AXSM's 68.20%. Michael Burry would worry about large intangible write-downs or revaluation gains overshadowing real performance.
-19.06%
Both yoy CFO lines are negative, with AXSM at -54.81%. Martin Whitman would suspect cyclical or cost factors harming the entire niche’s cash generation.
96.37%
CapEx growth of 96.37% while AXSM is zero at 0.00%. Bruce Berkowitz would see a mild cost burden that must yield returns in future revenue or margins.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-58.44%
We reduce yoy invests while AXSM stands at 0.00%. Joel Greenblatt sees near-term liquidity advantage unless competitor’s expansions yield high returns.
92.69%
Debt repayment growth of 92.69% while AXSM is zero at 0.00%. Bruce Berkowitz sees a mild advantage that can reduce interest costs unless expansions demand capital here.
-1494.87%
Negative yoy issuance while AXSM is 0.00%. Joel Greenblatt sees a near-term advantage in avoiding dilution unless competitor invests more effectively with the new shares.
No Data
No Data available this quarter, please select a different quarter.